These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37719614)

  • 21. CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis.
    Benden C; Schwarz C
    Pulm Ther; 2021 Dec; 7(2):377-393. PubMed ID: 34406641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
    Karb DB; Cummings LC
    Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of CFTR modulator therapies on CF airway microbiology.
    Rogers GB; Taylor SL; Hoffman LR; Burr LD
    J Cyst Fibros; 2020 May; 19(3):359-364. PubMed ID: 31416774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
    Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.
    Jones M; Moffatt F; Harvey A; Ryan JM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013610. PubMed ID: 37462324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators.
    Konrad J; Eber E; Stadlbauer V
    Paediatr Respir Rev; 2022 Jun; 42():9-16. PubMed ID: 33485777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
    Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
    Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
    Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
    Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.
    Pinto MC; Silva IAL; Figueira MF; Amaral MD; Lopes-Pacheco M
    J Exp Pharmacol; 2021; 13():693-723. PubMed ID: 34326672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis.
    Shiferaw D; Faruqi S
    Ther Clin Risk Manag; 2019; 15():1029-1040. PubMed ID: 31692517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis.
    Barton TE; Frost F; Fothergill JL; Neill DR
    J Med Microbiol; 2022 Dec; 71(12):. PubMed ID: 36748497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and novel therapeutic strategies for the management of cystic fibrosis.
    Gbian DL; Omri A
    Expert Opin Drug Deliv; 2021 May; 18(5):535-552. PubMed ID: 33426936
    [No Abstract]   [Full Text] [Related]  

  • 38. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.
    Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A
    Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives.
    Schmidt BZ; Haaf JB; Leal T; Noel S
    Clin Pharmacol; 2016; 8():127-140. PubMed ID: 27703398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
    Lopes-Pacheco M
    Front Pharmacol; 2019; 10():1662. PubMed ID: 32153386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.